10-Q: Ekso Bionics Reports First Quarter 2024 Results Amidst Liquidity Concerns

Ekso Bionics reported a net loss of $3.4 million for the first quarter of 2024, while also expressing substantial doubt about its ability to continue as a going concern.

Summary

• Ekso Bionics reported a net loss of $3.4 million for the first quarter of 2024, compared to a $4.4 million loss in the same period last year.
• Revenue decreased by 9% to $3.8 million, primarily due to lower sales in the EksoHealth segment, partially offset by increased sales in the EksoWorks segment.
• The company's gross profit remained relatively flat at $1.95 million, with a slight increase in gross margin to 52%.
• Operating expenses decreased by 19% to $5.2 million, mainly due to lower sales and marketing and general and administrative costs.
• The company's cash balance was $8.8 million as of March 31, 2024, with $2 million restricted due to a loan agreement.
• Management has expressed substantial doubt about the company's ability to continue as a going concern for the next 12 months, citing the need for additional financing.
• The company completed a registered direct offering in January 2024, raising approximately $3.9 million in net proceeds.

Sentiment

Score: 3

Explanation: The document expresses significant concerns about the company's financial health and ability to continue as a going concern, despite some improvements in net loss and gross margin. The need for additional financing and the going concern warning significantly weigh down the sentiment.

Positives

• The company's net loss decreased by $960 thousand compared to the same period last year.
• Gross margin improved by 3 percentage points year-over-year.
• Operating expenses were reduced by $1.2 million compared to the same period last year.
• The company successfully raised $3.9 million through a registered direct offering.
• The company has a non-cancellable backlog of $1.9 million.

Negatives

• Revenue decreased by 9% year-over-year.
• The company used $3.5 million of cash in operations during the quarter.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has $2 million of restricted cash due to a loan agreement.
• The company had two customers with an accounts receivable balance totaling 10% or more of the company's total accounts receivable as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to its history of operating losses and negative cash flows.
• The company's revenue is dependent on market demand for its exoskeleton products, which is influenced by various factors including economic conditions and reimbursement levels.
• The company's ability to obtain additional financing is not guaranteed, and failure to do so could lead to delays or abandonment of product development projects.
• The company is subject to risks related to regulatory approvals, clinical trials, and competition.
• The company's business is impacted by foreign currency fluctuations.

Future Outlook

Management intends to raise funds through one or more financings, but there is no assurance that the company will be able to complete such financings on acceptable terms or in amounts sufficient to continue operating the business under the operating plan. If the company is unable to complete sufficient additional financings, management plans include delaying or abandoning certain product development projects, cost reduction efforts for products, and refocused sales efforts to accelerate revenue growth above historical results.

Management Comments

• Management intends to raise funds through one or more financings.
• Management believes that substantial doubt exists about the company's ability to continue as a going concern for a period of at least 12 months from the date of issuance of these condensed consolidated financial statements.

Industry Context

The company operates in the medical device and robotics industry, which is characterized by high research and development costs, regulatory hurdles, and competition. The company's focus on exoskeleton technology for rehabilitation and industrial use positions it in a niche market with potential for growth, but also faces challenges related to market adoption and reimbursement.

Comparison to Industry Standards

• Ekso Bionics' revenue decline of 9% contrasts with some medical device companies that have shown growth in the same period, indicating potential challenges in market penetration or product demand.
• The company's gross margin of 52% is within the range of other medical device companies, but the company's operating expenses remain high relative to revenue, suggesting a need for further cost management.
• The company's cash position of $8.8 million, with $2 million restricted, is relatively low compared to some of its peers, highlighting the need for additional financing.
• The company's reliance on external financing is a common trait among early-stage medical device companies, but the going concern warning is a significant concern that is not typical of established companies in the sector.
• The company's focus on exoskeleton technology is a niche area within the broader medical device industry, making direct comparisons challenging, but the company's financial performance suggests it is facing significant headwinds.

Related Party Transactions

• The company entered into a mutual release and settlement agreement with an entity to settle and resolve any and all potential claims brought forth in connection with a consulting agreement executed between the entity and the company in July 2017. A member of the company's board of directors is affiliated with one of two entities under common control.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern warning and need for additional financing.
• Employees may be impacted by potential cost reduction efforts or delays in product development.
• Customers may be concerned about the company's ability to continue providing products and services.
• Creditors face increased risk due to the company's financial instability.

Next Steps

• The company intends to raise funds through one or more financings.
• The company plans to continue to explore business development initiatives to fuel growth and long-term value in its existing segments.
• The company will continue to leverage its EksoNR and Ekso Indego customer base to educate and mentor strategic target centers that specialize in stroke, ABI and SCI rehabilitation in specific geographies.
• The company plans to sell products to individuals in the Medicare market through Durable Medical Equipment suppliers (DMEs).

Key Dates

Keywords

exoskeleton, medical devices, rehabilitation, wearable technology, Ekso Bionics, financial results, liquidity, going concern, revenue, net loss, operating expenses, financing, warrants, healthcare, robotics